

**DISPOSITION:** September 30, 1953. Default decree of condemnation. The court ordered that the devices and testimonial letters be delivered to the Food and Drug Administration.

**DRUGS AND DEVICES ACTIONABLE BECAUSE OF DEVIATION  
FROM OFFICIAL OR OWN STANDARDS**

**4191. Adulteration of posterior pituitary injection. U. S. v. Cleo O. Bedwell.**  
Plea of nolo contendere. Fine, \$50. (F. D. C. No. 33778. Sample Nos. 17304-L, 17329-L.)

**INFORMATION FILED:** June 2, 1953, Southern District of California, against Cleo O. Bedwell, president of the Coast Chemical Co., a corporation, Los Angeles, Calif.

**ALLEGED VIOLATION:** On or about January 18 and May 1, 1952, the defendant caused to be given to firms engaged in the business of shipping drugs in interstate commerce, invoices containing guaranties to the effect that the *posterior pituitary injection* listed in the invoices and delivered by the defendant under the guaranties would not be adulterated. On or about January 18 and May 1, 1952, the defendant caused to be delivered to the holders of the guaranties, at Los Angeles, Calif., quantities of *posterior pituitary injections* which were adulterated.

**LABEL, IN PART:** (Vials) "Post Pituitary Solution U. S. P. \* \* \* Towne, Paulsen & Co., Inc. Distributors Pasadena, Cal." and "Obstétrical Pituitary U. S. P. \* \* \* Medical Specialties Co. Los Angeles, Calif."

**NATURE OF CHARGE:** Adulteration, Section 501 (b), the article purported to be and was represented as "Posterior Pituitary Injection," a drug the name of which is recognized in the United States Pharmacopeia, an official compendium, and its strength differed from the official standard since each cubic centimeter of the article possessed an activity equivalent to less than 8.5 U. S. P. posterior pituitary units, whereas the standard provides that each cubic centimeter of posterior pituitary injection possesses an activity equivalent to not less than 8.5 U. S. P. posterior pituitary units; and the difference in strength of the article from the standard was not plainly stated, or stated at all, on its label.

**DISPOSITION:** August 17, 1953. The defendant having entered a plea of nolo contendere, the court fined him \$50.

**4192. Adulteration and misbranding of Yale Testrex tablets. U. S. v. Captivante Laboratories, Inc., and Paul Thomas. Pleas of guilty. Fine of \$150 against corporation and \$300 against individual. (F. D. C. No. 34860. Sample Nos. 32442-L, 32449-L, 34692-L.)**

**INFORMATION FILED:** May 6, 1953, Southern District of New York, against Captivante Laboratories, Inc., New York, N. Y., and Paul Thomas, president of the corporation.

**ALLEGED SHIPMENT:** On or about March 28, April 22, and May 29, 1952, from the State of New York into the State of Arkansas.

**NATURE OF CHARGE:** Adulteration, Section 501 (c), the strength of the article differed from that which it was represented to possess. Some of the tablets were represented to contain 2.5 milligrams of methyltestosterone and other tablets were represented to contain 5 milligrams of methyltestosterone, whereas the tablets contained less methyltestosterone than represented.